P A Coffie MD PhD); Programme PAC-CI, Abidjan, Côte d'Ivoire (P A Coffie, M G Kouamé MD PhD); stichting hiv monitoring, Amsterdam, Netherlands ( - Archive ouverte HAL Access content directly
Journal Articles The Lancet HIV Year : 2022

P A Coffie MD PhD); Programme PAC-CI, Abidjan, Côte d'Ivoire (P A Coffie, M G Kouamé MD PhD); stichting hiv monitoring, Amsterdam, Netherlands (

(1, 2) , (3, 4) , (1, 5) , (6, 7) , (7) , (8, 9) , (2, 1) , (2, 1)
1
2
3
4
5
6
7
8
9

Abstract

Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy. Considering that tenofovir potently inhibits HBV, providing PrEP to individuals with HBV effectively results in treatment of their HBV infection. However, some clinicians might be hesitant to initiate PrEP in people with chronic HBV due to unknown risks of HBV reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. Unfortunately, these knowledge gaps affect scale up of PrEP among people with chronic HBV. Emerging data regarding the risks and benefits of antiviral cessation in people with chronic HBV suggest that PrEP can be safely initiated despite the risks of non-adherence or discontinuation. People with chronic HBV who stop PrEP should be closely monitored for HBV reactivation and hepatitis flares after antiviral cessation.
Embargoed file
Embargoed file
0 9 22
Year Month Jours
Avant la publication

Dates and versions

ird-03879814 , version 1 (30-11-2022)

Identifiers

Cite

Amir M Mohareb, Joseph Larmarange, Arthur Y Kim, Patrick A Coffie, Menan Gérard Kouamé, et al.. P A Coffie MD PhD); Programme PAC-CI, Abidjan, Côte d'Ivoire (P A Coffie, M G Kouamé MD PhD); stichting hiv monitoring, Amsterdam, Netherlands (. The Lancet HIV, 2022, Lancet HIV, 9 (8), pp.e585-e594. ⟨10.1016/S2352-3018⟩. ⟨ird-03879814⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More